AVANT technology offers multiple opportunities for the development of novel vaccines that prevent serious viral infections. AVANT currently has two viral vaccines programs: Rotarix® being commercialized in collaboration with GlaxoSmithKline, and a novel virus-like particles (VLPs)technology platform licensed from Select Vaccines Limited that addresses seasonal and pandemic influenza.